Phase 1/2 Study Of Rx-3117, An Oral Antimetabolite Nucleoside, In Combination With Nab-Paclitaxel (Nab-Pac) As First Line Treatment of Metastatic Pancreatic Cancer (Met-Pc):Preliminary Results Jan 18, 2019
RX-3117, A Novel, Oral Nucleoside Analog, in Combination with Nab-paclitaxel (NAB-PAC) in First-line Metastatic Pancreatic Cancer (MET-PC): Safety, Tolerability, and Preliminary Responses Oct 2, 2018
Preliminary Results From an Ongoing Phase 2a Study of RX-3117, an Oral Nucleoside Analogue to Treat Advanced Urothelial Cancer (aUC) Jun 1, 2018
Preliminary Report of A Phase 1b/2a Trial, An Oral Inhibitor of Phosphorylated P68 (P-p68), Which Mediates β-catenin Nuclear Translocation in Advanced Triple-Negative Breast Cancer (TNBC) Jun 1, 2018
RX-3117 promotes epigenetic effects in cancer cells through enhanced degradation of DNMT1 Apr 14, 2018
RX-3117, an Oral Hypomethylating Agent to Treat Advanced Solid Tumors (ST): Interim results from an Ongoing Phase 2a Study in Advance Urothelial Cancer (aUC) Feb 8, 2018
RX3117: Activity of an Oral Antimetabolite Nucleoside in Subjects with Pancreatic Cancer – Preliminary Results of Stage II of the Phase Ia/IIb Study Jan 18, 2018
Preclinical studies of RX-5902, a beta-catenin modulator in triple negative breast cancer Dec 5, 2017
A Novel Small Molecule Nucleoside Analog, RX-3117, Shows Potent Therapeutic Activity in Combination with Nab-paclitaxel and Checkpoint Inhibitors in Xenograft Models Sep 11, 2017
Phase 1 study of RX-5902, a novel Orally Bioavailable Inhibitor of Phosphorylated P68, which prevents β-catenin Translocation in Advanced Solid Tumors Sep 11, 2017
